SCG3

Summary

SCG3 (secretogranin III, HGNC:13707) is a protein-coding gene on chromosome 15q21.2, encoding Secretogranin-3 (Q8WXD2). Member of the granin protein family that regulates the biogenesis of secretory granules.

The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins. Granins may serve as precursors for biologically active peptides. Some granins have been shown to function as helper proteins in sorting and proteolytic processing of prohormones; however, the function of this protein is unknown. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 29106 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 60 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_013243

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13707
Approved symbol	SCG3
Name	secretogranin III
Location	15q21.2
Locus type	gene with protein product
Status	Approved
Aliases	SgIII, FLJ90833
Ensembl gene	ENSG00000104112
Ensembl biotype	protein_coding
OMIM	611796
Entrez	29106

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000220478, ENST00000542355, ENST00000558709, ENST00000919607, ENST00000919608, ENST00000919609, ENST00000919610

RefSeq mRNA: 2 — MANE Select: NM_013243 NM_001165257, NM_013243

CCDS: CCDS10142, CCDS53947

Canonical transcript exons

ENST00000220478 — 12 exons

Exon	Start	End
ENSE00000688708	51682517	51682569
ENSE00000688716	51695875	51695991
ENSE00000688717	51699319	51699402
ENSE00000688718	51701107	51701244
ENSE00001102751	51713333	51713413
ENSE00002548153	51719408	51721026
ENSE00002557357	51681503	51681837
ENSE00003466518	51683079	51683124
ENSE00003478370	51688260	51688402
ENSE00003541136	51689219	51689368
ENSE00003580435	51692159	51692336
ENSE00003657453	51683219	51683434

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 98.22.

FANTOM5 (CAGE): breadth broad, TPM avg 21.5443 / max 1751.1409, expressed in 413 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146658	12.3866	327
146660	6.3464	319
146659	2.1125	162
146657	0.5876	138
146664	0.1112	40

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
islet of Langerhans	UBERON:0000006	98.22	gold quality
cortical plate	UBERON:0005343	97.95	gold quality
type B pancreatic cell	CL:0000169	97.91	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.56	gold quality
right frontal lobe	UBERON:0002810	97.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.18	gold quality
anterior cingulate cortex	UBERON:0009835	97.03	gold quality
prefrontal cortex	UBERON:0000451	96.96	gold quality
cingulate cortex	UBERON:0003027	96.94	gold quality
ganglionic eminence	UBERON:0004023	96.39	gold quality
frontal cortex	UBERON:0001870	96.16	gold quality
neocortex	UBERON:0001950	96.05	gold quality
amygdala	UBERON:0001876	95.78	gold quality
cerebral cortex	UBERON:0000956	95.38	gold quality
caudate nucleus	UBERON:0001873	94.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.77	gold quality
primary visual cortex	UBERON:0002436	94.70	gold quality
telencephalon	UBERON:0001893	94.60	gold quality
putamen	UBERON:0001874	94.38	gold quality
cerebellar cortex	UBERON:0002129	94.17	gold quality
cerebellar hemisphere	UBERON:0002245	94.16	gold quality
forebrain	UBERON:0001890	93.92	gold quality
temporal lobe	UBERON:0001871	93.88	gold quality
nucleus accumbens	UBERON:0001882	93.71	gold quality
cerebellum	UBERON:0002037	93.57	gold quality
brain	UBERON:0000955	93.34	gold quality
superior frontal gyrus	UBERON:0002661	93.31	gold quality
Ammon’s horn	UBERON:0001954	92.69	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.27	gold quality
entorhinal cortex	UBERON:0002728	92.20	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	1961.79
E-GEOD-83139	yes	1430.36
E-MTAB-9435	yes	556.77
E-MTAB-9388	yes	345.71
E-HCAD-5	yes	44.98
E-GEOD-84465	yes	24.95
E-GEOD-81547	yes	20.65
E-MTAB-5061	yes	19.18
E-GEOD-93593	yes	14.61
E-ANND-3	yes	12.74
E-CURD-114	yes	12.71
E-GEOD-125970	yes	6.42
E-HCAD-10	yes	3.89
E-ENAD-27	no	1267.16
E-HCAD-31	no	24.61

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ASCL1, REST

miRNA regulators (miRDB)

71 targeting SCG3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-567	99.63	68.57	1219

Literature-anchored findings (GeneRIF, showing 14)

• Genetic variations in the SCG3 gene may influence the risk of obesity through possible regulation of hypothalamic neuropeptide secretion. (PMID:17200173)
• Secretogranins III assays failed to detect increased concentrations in any of the patients with neuroendocrine tumours. (PMID:18448176)
• these data suggest that SgIII, DMT-1 and HNP-1 are implicated in cell-mediated LDL oxidation. (PMID:19150442)
• SgIII was expressed in 41 of 47 neuroendocrine tumours. The expression of SgIII agreed well with that of CgA, CgB and SgII, with exceptions of phaeochromocytomas and parathyroid adenomas. (PMID:20550951)
• This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. (PMID:21046454)
• Our data suggest that genetic variations in the FTO, SCG3 and MTMR9 genes independently influence the risk of metabolic syndrome. (PMID:21796137)
• SCG3 may be involved in apoptosis signal transduction as a caspase substrate.It may be a pivotal component of the neuroendocrine pathway & play an important role in neuronal communication & neurotransmitter release. (PMID:22987761)
• SCG3 is essential in the process and targeting of neuropeptides and neurotrophins, its participation in the pathological progression of Alzheimer’s disease may be suggested (PMID:22998035)
• HBXIP facilitates the proliferation of hepatoma cells by up-regulating SCG3 via E2F1 and miR-509-3p modulation. (PMID:24882622)
• This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as “selective angiogenesis blockers” for targeted therapy of diabetic retinopathy. [review] (PMID:28856381)
• results suggested an association between the fucosylated glycoform of short-form SgIII and Small Cell Lung Carcinoma (PMID:28949141)
• SCG3 may be involved in PQinduced astrocyte activation via regulation of the expression and selective recruitment of cellular factors, thus suggesting that SCG3 may represent an indicator of astrocyte activation. (PMID:30280190)
• Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. (PMID:34062733)
• SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes. (PMID:34257545)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	scg3	ENSDARG00000086288
mus_musculus	Scg3	ENSMUSG00000032181
rattus_norvegicus	Scg3	ENSRNOG00000010784

Protein

Protein identifiers

Secretogranin-3 — Q8WXD2 (reviewed: Q8WXD2)

Alternative names: Secretogranin III

All UniProt accessions (2): Q8WXD2, H0YKC2

UniProt curated annotations — full annotation on UniProt →

Function. Member of the granin protein family that regulates the biogenesis of secretory granules. Acts as a sorting receptor for intragranular proteins including chromogranin A/CHGA. May also play a role in angiogenesis. Promotes endothelial proliferation, migration and tube formation through MEK/ERK signaling pathway.

Subunit / interactions. Interacts with CHGA. Interacts with secretogranin II/SCG2. Interacts (via C-terminus) with CPE.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Secretory vesicle membrane. Secreted.

Tissue specificity. Detected in urine (at protein level). Expressed in brain, heart, kidney, liver and skeletal muscle.

Post-translational modifications. O-glycosylated.

Polymorphism. Polymorphisms in the 5’-flanking region and in intron 1 may have an effect on transcriptional activity and be associated with an increase in subcutaneous, but not visceral, fat area. Hence, may influence the risk of obesity.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WXD2-1	1	yes
Q8WXD2-2	2

RefSeq proteins (2): NP_001158729, NP_037375* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026197	SCG3	Family

Pfam: PF15467

UniProt features (20 total): glycosylation site 4, sequence conflict 4, sequence variant 3, region of interest 2, compositionally biased region 2, modified residue 2, signal peptide 1, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WXD2-F1	59.57	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 37, 362

Glycosylation sites (4): 231, 359, 37, 216

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation
R-HSA-109582	Hemostasis
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-76002	Platelet activation, signaling and aggregation
R-HSA-76005	Response to elevated platelet cytosolic Ca2+

MSigDB gene sets: 138 (showing top): GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, FOXD3_01, MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN, TCF4_Q5, HFH8_01, FOXJ2_01, HFH4_01, HFH3_01, HFH1_01, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, RGAGGAARY_PU1_Q6, CCCNNGGGAR_OLF1_01, YYCATTCAWW_UNKNOWN, FOX_Q2

GO Biological Process (1): protein localization to secretory granule (GO:0033366)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), endoplasmic reticulum lumen (GO:0005788), transport vesicle membrane (GO:0030658), secretory granule membrane (GO:0030667), secretory granule lumen (GO:0034774), membrane (GO:0016020), transport vesicle (GO:0030133), cytoplasmic vesicle (GO:0031410)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Metabolism of proteins	2
Response to elevated platelet cytosolic Ca2+	1
Post-translational protein modification	1
Hemostasis	1
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cytoplasmic vesicle membrane	2
bounding membrane of organelle	2
secretory granule	2
protein localization to organelle	1
nucleic acid binding	1
binding	1
endoplasmic reticulum	1
intracellular organelle lumen	1
transport vesicle	1
cytoplasmic vesicle lumen	1
endomembrane system	1
cytoplasmic vesicle	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

1170 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCG3	CHGA	P10645	985
SCG3	SCG2	P13521	908
SCG3	SCG5	P01164	907
SCG3	CHGB	P05060	895
SCG3	TRPA1	O75762	807
SCG3	CPE	P16870	783
SCG3	PMCH	P20382	749
SCG3	POMC	P01189	743
SCG3	PCSK1N	Q9UHG2	635
SCG3	GNAS	Q5JWF2	608
SCG3	VGF	O15240	604
SCG3	NPY	P01303	574
SCG3	HCRT	O43612	538
SCG3	RASSF2	P50749	464
SCG3	PAM	P19021	434

IntAct

13 interactions, top by confidence:

A	B	Type	Score
SDCBP	SCG3	psi-mi:“MI:0915”(physical association)	0.560
SCG3	SCG2	psi-mi:“MI:0915”(physical association)	0.510
SCG3	FAM20C	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
DNM1L	SCG3	psi-mi:“MI:0915”(physical association)	0.370
MAPT	MEX3A	psi-mi:“MI:0914”(association)	0.350
SCG3	TPM2	psi-mi:“MI:0914”(association)	0.350
SCG3	CTH	psi-mi:“MI:0914”(association)	0.350
SDCBP	SCG3	psi-mi:“MI:0915”(physical association)	0.000
SCG3	SDCBP	psi-mi:“MI:0915”(physical association)	0.000
NRIP1	SCG3	psi-mi:“MI:0915”(physical association)	0.000
NCAM2	SCG3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): SCG3 (Two-hybrid), IRGQ (Affinity Capture-MS), MRE11A (Affinity Capture-MS), CTH (Affinity Capture-MS), TPM2 (Affinity Capture-MS), SCG3 (Affinity Capture-MS), SCG3 (Synthetic Lethality), SDCBP (Two-hybrid), SCG3 (Positive Genetic), IRGQ (Affinity Capture-MS), CTH (Affinity Capture-MS), SCG3 (Two-hybrid), SCG3 (Two-hybrid), SCG3 (Cross-Linking-MS (XL-MS)), SCG3 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A1S4FQ37, A0A6B9L4T1, A2XAM1, A3KQQ9, A3RGB1, A6QLI2, D1FQ14, F5HF90, F7E728, H2A0M1, H7C7P1, O01949, O94356, P04923, P04926, P08725, P13828, P16845, P32778, P36046, P47868, P53278, P86958, Q02448, Q04807, Q19970, Q3T146, Q3V2D2, Q45206, Q45214, Q45215, Q54IN6, Q5MIT9, Q6R7H2, Q6UWT4, Q7YT37, Q8SRT0, Q8SV33, Q8SWP0, Q8T117

Diamond homologs: A3KQQ9, A6QLI2, F7E728, P47867, P47868, Q8WXD2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3137 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:51688386:T:C	L175P	0.996
15:51688329:C:A	A156D	0.995
15:51688364:T:C	F168L	0.994
15:51688366:T:A	F168L	0.994
15:51688366:T:G	F168L	0.994
15:51695902:T:C	L299P	0.994
15:51688401:T:C	L180P	0.993
15:51695923:T:C	L306P	0.993
15:51688328:G:C	A156P	0.992
15:51695989:T:C	L328P	0.991
15:51688365:T:G	F168C	0.990
15:51695931:T:C	F309L	0.989
15:51695933:T:A	F309L	0.989
15:51695933:T:G	F309L	0.989
15:51695976:G:C	G324R	0.989
15:51719449:G:C	A444P	0.989
15:51688326:T:A	I155N	0.987
15:51688338:T:C	I159T	0.987
15:51688326:T:G	I155S	0.986
15:51688377:T:A	V172D	0.986
15:51688386:T:A	L175Q	0.986
15:51688389:T:C	L176P	0.986
15:51689268:T:C	L197S	0.986
15:51688395:T:C	L178P	0.985
15:51689244:T:C	L189P	0.985
15:51688338:T:G	I159S	0.983
15:51695989:T:A	L328H	0.983
15:51689258:G:C	A194P	0.982
15:51692316:T:C	L283P	0.982
15:51692319:T:C	L284P	0.982

dbSNP variants (sampled 300 via entrez): RS1000193278 (15:51689489 G>A), RS1000225753 (15:51689850 G>A), RS1000281281 (15:51721308 C>T), RS1000290589 (15:51681081 T>C), RS1000455944 (15:51718628 A>G), RS1000496419 (15:51688208 A>C,G,T), RS1000560157 (15:51688409 C>T), RS1000562556 (15:51708350 T>C), RS1000594289 (15:51686811 T>C), RS1000670808 (15:51717553 A>AC), RS1000810213 (15:51683666 T>A,G), RS1000893186 (15:51714319 G>A), RS1000912246 (15:51701893 C>T), RS1000936162 (15:51699353 A>G), RS1001020987 (15:51686466 T>G)

Disease associations

OMIM: gene MIM:611796 | disease phenotypes: MIM:181500

GenCC curated gene-disease

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (1): NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
entinostat	decreases expression, increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Paraquat	decreases reaction, affects localization, increases expression, increases secretion, decreases expression	2
methylmercuric chloride	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
trichostatin A	increases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
benzyloxycarbonyl-valyl-alanyl-aspartic acid	decreases expression, decreases reaction	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	affects cotreatment, increases expression, decreases expression	1
Lead	affects splicing	1
Mercury	increases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Triclosan	increases expression	1
Tunicamycin	increases expression	1
Antirheumatic Agents	decreases expression	1
Zinc Sulfate	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety